◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › HRTX

Heron Therapeutics, Inc. (HRTX) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-09

Heron Therapeutics, Inc. (HRTX) operates in the Biotechnology industry and is headquartered in Cary, United States with about 128 employees. Its market capitalization is roughly $81 million. In the fiscal year ended 2025-12-31, HRTX reported $155M in revenue and ($20M) in net income.

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care.

Interactive charts & full statements → Open the HRTX valuation workbench →

HRTX Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue$155M$144M$127M$108M
Gross Profit$114M$106M$62M$53M
Operating Income (EBIT)($2M)($12M)($111M)($175M)
Net Income($20M)($14M)($111M)($182M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HRTX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$35M$41M$38M$37M$39M
Gross Profit$24M$30M$26M$27M$30M
Operating Income (EBIT)($5M)$0M($4M)($2M)$3M
Net Income($8M)($3M)($18M)($2M)$3M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HRTX Free Cash Flow History

HRTX Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$256M$233M$222M$251M
Total Liabilities$242M$267M$256M$237M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive HRTX viewer.

Other Companies in Biotechnology

← HRTGAll stocksHRZN →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.